Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational 6‑month follow‑up of COVID‑19 patients previously treated in RO7496998 (AT‑527) trials
2021-000627-12Phase 3Completed
- Sponsor
- Roche
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bemnifosbuvir in coronavirus disease 2019 (COVID-19), sponsored by Roche. Primary endpoint: Long-term COVID-19 symptom trajectories. Started May 2021; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000627-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000627-12.